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Summary 
In the MCL-002 study, lenalidomide demonstrated significantly improved median 
progression-free survival (PFS) compared with investigator’s choice (IC) in patients with 
relapsed/refractory mantle cell lymphoma (MCL). Here we provide long-term follow-up 
data and results of preplanned subgroup exploratory analyses from MCL-002 to 
evaluate the potential impact of demographic factors, baseline clinical characteristics, 
and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were 
randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1–21; 28-day cycles) 
or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil, or 
cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n=170; 
IC, n=84). Subgroup analyses of PFS favored lenalidomide over IC across most 
characteristics, including risk factors such as high MCL International Prognostic Index 
score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high 
tumor burden, and refractoriness to last prior therapy. By multivariate Cox regression 
analysis, factors associated with significantly longer PFS—other than lenalidomide 
treatment—included normal LDH levels (P<0.001), nonbulky disease (P=0.045), <3 
prior antilymphoma treatments (P=0.005), and ≥6 months since last prior treatment 
(P=0.032). Overall, lenalidomide improved PFS versus single-agent IC therapy in 
patients with relapsed/refractory MCL, irrespective of many demographic factors, 
disease characteristics, and prior treatment history. 
 
Keywords: lenalidomide; mantle cell lymphoma; non-Hodgkin lymphoma 
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Introduction 
Mantle cell lymphoma (MCL) accounts for ~6% of all cases of non-Hodgkin lymphoma 
(NHL) and typically presents as advanced-stage disease in patients over 60 years of 
age (Avivi and Goy 2015). First-line dose-intensive chemoimmunotherapy with or 
without stem cell transplantation leads to progression-free survival (PFS) improvement 
in younger patients with MCL and an overall fit status (Dreyling, et al 2014). Older 
patients with multiple comorbidities are usually treated with less aggressive regimens. 
MCL typically relapses and becomes increasingly more challenging to manage over the 
course of the disease. With current therapies in the relapsed/refractory setting 
(bortezomib, temsirolimus, lenalidomide, and ibrutinib), median overall survival (OS) 
following relapse is ~2 years (Avivi and Goy 2015). While multiple treatment options are 
available, some with proven benefit in randomized trials (eg, lenalidomide, ibrutinib), 
their role in the standard of care for relapsed/refractory disease and the best possible 
treatment sequence remains to be defined (Avivi and Goy 2015, Dreyling, et al 2014). 
 Lenalidomide is an oral IMiD® immunomodulatory agent, with direct and immune-
mediated mechanisms of action (Gribben, et al 2015) and has shown clinical activity 
and safety in multiple studies, including 2 single-arm, phase II trials (NHL-002 and NHL-
003) in heavily pretreated patients with relapsed/refractory aggressive NHL, including 
MCL (Habermann, et al 2009, Zinzani, et al 2013). Subsequently in the single-arm, 
phase II MCL-001 (EMERGE) study in 134 patients with MCL who had relapsed during 
treatment with or developed disease refractory disease to bortezomib, lenalidomide 
treatment resulted in an overall response rate (ORR) of 28%, with a median response 
duration of 16.6 months (Goy, et al 2015, Goy, et al 2013). More recently, in the 
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randomized, open-label, multicenter, phase II MCL-002 (SPRINT) study, the 
lenalidomide arm had a statistically significant and clinically meaningful improvement in 
the primary endpoint of PFS compared with investigator’s choice (IC) of single-agent 
therapy (rituximab, gemcitabine, fludarabine, chlorambucil, or cytarabine), with a 
manageable safety profile (Trneny, et al 2016). This primary analysis of MCL-002—
which had a cutoff date of 07March2014 and a median follow-up of 15.9 months for the 
overall study population—found a median PFS of 8.7 months for lenalidomide versus 
5.2 months for IC (hazard ratio [HR] 0.61, 95% CI 0.44-0.84; P = 0.004). Per the study 
protocol, follow-up to MCL-002 continues until the death of 70% of patients, median 
follow-up of responding patients is greater than 2 years, median duration of response 
has been reached, or 4 years have passed from last patient randomization, whichever 
comes later. 
 In the present report, we provide long-term follow-up data and results of 
preplanned subgroup exploratory analyses from the MCL-002 study to evaluate the 
potential impact of demographic factors, baseline clinical characteristics, and prior 
therapies on PFS in patients with relapsed/refractory MCL randomized to receive 
lenalidomide versus IC. 
 
Patients and methods 
Study design 
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The methodology for MCL-002 (ClinicalTrials.gov identifier, NCT00875667) has been 
previously described (Trneny, et al 2016). Key inclusion criteria were minimum age 18 
years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, 
histologically confirmed MCL with cyclin D1 overexpression by immunohistochemistry, 
measurable disease ≥2 cm in the longest diameter, refractory to prior therapy or ≤3 
relapses and had documented progressive disease after ≥1 prior combination 
chemotherapy regimen with an alkylating agent and an anthracycline, cytarabine, and/or 
fludarabine (with or without rituximab); and ineligibility for intensive chemotherapy or 
stem cell transplantation (SCT). Patients were stratified by time from diagnosis (<3 
versus ≥3 years), time from last antilymphoma therapy (<6 versus ≥6 months), and prior 
autologous SCT and randomized 2:1 to lenalidomide or IC. Oral lenalidomide was 
initiated at 25 mg/day, days 1–21 of each 28-day cycle until progressive disease (PD) or 
as tolerated. Rituximab and chlorambucil were administered until PD or unacceptable 
toxicity, whereas gemcitabine, fludarabine, and cytarabine were given for ≤6 cycles. 
Patients randomized to IC were allowed to cross over to lenalidomide following 
documented PD.  
 All patients provided written informed consent prior to study initiation. The study 
protocol and its amendments were approved by an institutional review board or 
independent ethics committee, or centrally if required by national regulations, and were 
conducted in accordance with the ethical principles of the Declaration of Helsinki and in 
compliance with Good Clinical Practice.  
Post hoc assessments 
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As prospectively outlined in the study protocol, planned analyses for longer follow-up 
were performed by investigator assessment to evaluate PFS in the overall study 
population and for prespecified subgroups at baseline (i.e., the time of randomization 
unless otherwise stated). These subgroups are grouped in 3 categories based on their 
association with MCL International Prognostic Index (MIPI) scoring, other patient 
characteristics, and treatment history. Specific parameters and cut-off/comparison 
values within each subgroup are defined in supplementary Table SI. 
 We evaluated PFS in the intent-to-treat (ITT) population which included all 
randomized patients irrespective of receipt of study treatment. Computed tomography 
(CT) scans (or magnetic resonance imaging if CT was contraindicated) were performed 
every 2 cycles (±7 days) for 6 months and then every 90 days (±15 days) until 
documented PD or death.  
Statistical analyses 
PFS was characterized by Kaplan-Meier estimates with P values per log-rank test with 
determination of median values and 95% confidence interval (CI). Univariate and 
multivariate Cox regression models evaluated whether baseline subgroup factors were 
predictive of the risk of progression or death. Variables with a P value <0.20 by 
univariate analysis were selected for multivariate analysis. Final variables were selected 
using a stepwise selection method with entry level P = 0.20 and stay level P = 0.15. 
ORR was defined according to Cheson et al (Cheson, et al 1999) and statistical 
significance determined by Wald Χ2 test (P < 0.05). 
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Results 
Patient demographics and disposition 
The ITT population comprised 254 patients (n=170 lenalidomide; n=84 IC) enrolled 
between April 2009 and March 2013. Three patients randomized to lenalidomide and 1 
patient randomized to IC did not receive study treatment. Overall, patients had a median 
age of 68.5 years, 68% were 65 years or older, and 73% were male. Patients had 
received a median of 2 (range, 1–5) prior treatment regimens, including 19% with prior 
SCT. As previously reported, the treatment arms were balanced in baseline 
characteristics except for high-risk MIPI score, high tumor burden, bulky disease, and 
high lactate dehydrogenase (LDH) concentration which were more prevalent among 
patients randomized to lenalidomide versus IC (Trneny, et al 2016). Also, compared 
with the IC treatment arm, more patients in the lenalidomide arm had received a higher 
number of previous anti-lymphoma treatments and had been refractory to their last 
previous therapy.  
As of the data cutoff of March 7, 2016, 163 of 250 patients (65%) overall who 
received treatment had died. While on study, only 17 (7%) patients had died during or 
within 30 days of their study treatment (lenalidomide or IC). Causes of death were 
similar in both treatment groups, primarily due to malignant lymphoma (46% 
lenalidomide vs. 45% IC), other/unknown causes (17% lenalidomide vs 20% IC), and 
toxicity (1 lenalidomide patient vs 2 IC patients). 16 patients were ongoing on initial 
lenalidomide treatment and 1 patient in the IC (rituximab) group. Additionally, 5 of 40 
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patients who crossed over from IC to lenalidomide were still receiving lenalidomide 
treatment.  
Progression-free survival 
The median follow-up for all surviving patients was 41.3 months, which was an 
additional 20 months from the initial assessment and published report (Trneny, et al 
2016). Lenalidomide continued to show longer median PFS than IC (8.6 versus 5.4 
months, respectively; P = 0.006; Fig 1A). An improvement in PFS with lenalidomide 
over IC was evident across most baseline subgroups, particularly those with higher 
numbers of patients, and including patients who were ≥65 years of age (P = 0.001; Fig 
1B); had advanced stage III/IV disease at diagnosis (P = 0.014; Fig 1C), high LDH (P = 
0.016; Fig 1D]), high tumor burden (P = 0.007; Fig 1E), bulky disease (P = 0.068; Fig 
1F); and whose disease was refractory to their last therapy (P < 0.001; Fig 1G). In 
support of higher PFS in these same categories, lenalidomide treatment showed higher 
ORR compared with IC at the earliest efficacy assessment (cycle 3) when treatment on 
all IC comparators was still ongoing (supplementary Figure S1).  
 Figure 2 lists the total number of patients per arm and subgroup depicted in the 
forest plots, along with their associated median PFS values and P value. Subgroup data 
were missing for some patients. As shown in Figure 2A, subgroups that had statistically 
significant improvements in PFS favoring lenalidomide over IC included patients with 
intermediate (P = 0.033) and high MIPI score at baseline (P = 0.037), age ≥65 years (P 
= 0.001), ECOG PS 0–1 (P = 0.025) or 2–4 (P = 0.019), normal (P = 0.049) or high LDH 
(P = 0.016), and <6.7x109/L white blood cell (WBC) counts (P = 0.011). The analysis of 
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other patient and disease characteristics (Fig 2B) showed statistically significant 
improvements in PFS favoring lenalidomide in females (P = 0.035), stage III/IV disease 
at diagnosis (P = 0.014), irrespective of tumor burden (low P = 0.018; high P = 0.007), in 
patients without bulky disease (P = 0.004) or bone marrow involvement (P = 0.006), and 
in patients with both normal (P = 0.026) and moderate renal function (P = 0.019).  
 We also evaluated subgroups to examine the potential impact of prior therapy on 
PFS outcomes. As shown in Figure 2C, lenalidomide significantly improved PFS 
compared with IC in patients who were <3 years from MCL diagnosis (P = 0.002); had 
more prior systemic antilymphoma therapies (P = 0.002 for ≥2; P = 0.020 for ≥3 ); were 
refractory to their last therapy (P < 0.001); had >1 prior relapses (P = 0.007 for >1, P = 
0.007 for ≥2, and P = 0.006 for <3); regardless of time from last prior therapy (P = 0.042 
for <6 months, and P = 0.033 for ≥6 months); received prior rituximab- (P = 0.014) or 
fludarabine-including therapy (P = 0.038); and had not received prior high-dose therapy 
(HDT; P = 0.003) or undergone prior SCT (P = 0.003). Despite the limitation of small 
patient numbers in some subgroups, these data suggest that lenalidomide may 
significantly improve PFS compared with IC treatment irrespective of ECOG status, high 
LDH, and tumor burden.  
Univariate and multivariate analyses for progression-free survival 
Further evaluation of subgroups by univariate Cox regression analysis showed that 
treatment group (lenalidomide favored over IC) was the main effect associated with 
significantly improved PFS (HR = 0.65; P = 0.005), which was also highly significant by 
multivariate analysis (HR = 0.42; P < 0.001) (Table I). Other subgroups with statistically 
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significant improvements in PFS (P<0.05) in the univariate analysis were 
low/intermediate MIPI score at diagnosis and baseline, normal LDH levels, <10x109/L 
WBC counts, normal renal function, <3 prior systemic antilymphoma therapies, and ≥6 
months since last prior therapy .  
 In the multivariate Cox regression analysis, normal LDH level was associated 
with highly significant improvement in PFS (P < 0.001) with lenalidomide treatment 
versus IC (Table I). Other factors retaining significance in the multivariate model 
included no bulky disease (P = 0.045), <3 prior antilymphoma treatments (P = 0.005), 
and ≥6 months since last prior therapy (P = 0.032).  
Univariate and multivariate analyses for overall survival 
Median overall survival was 27.8 months (95% CI, 22.6-35.3) for lenalidomide versus 
21.2 months (95% CI, 16.0-31.7) for IC (HR = 0.86; 95% CI, 0.62-1.18; Mantel-Byar P = 
0.34 [taking into account the effect of crossover]; Fig 3). We also performed univariate 
and multivariate analyses for OS as a way of identifying and/or confirming the role of 
potential independent factors on survival (Table II). For OS, although the comparison 
between treatment groups did not achieve statistical significance (lenalidomide versus 
IC), baseline factors that were statistically significant in the univariate analysis (P < 
0.05) and led to improved OS were ECOG PS 0–1, normal LDH, low/intermediate MIPI 
score at diagnosis or baseline, <3 prior antilymphoma therapies, relapsed status to last 
therapy, ≥6 months from last prior therapy, low tumor burden, and no bulky disease. 
Significant in the multivariate analysis of OS was female sex (HR = 0.54; 95% CI, 0.33–
0.89; P = 0.015). 
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The primary analysis of MCL-002 demonstrated that lenalidomide significantly improved 
PFS compared with single-agent IC therapy in patients with relapsed/refractory MCL, 
resulting in a significant risk reduction in PD or death (Trneny, et al 2016). The current 
exploratory subgroup and multivariate analyses extend these findings by uncovering an 
improved clinical benefit with lenalidomide compared with IC in patients with a wide 
range of demographic and baseline clinical characteristics. Moreover, the PFS benefit of 
lenalidomide over IC does not appear to be affected by the level of disease activity 
(measured by increased LDH), more advanced stage MCL, or tumor burden. 
Additionally, lenalidomide treatment showed an early significant improvement in ORR 
compared with IC at cycle 3, supporting later differences in PFS. The PFS advantage of 
lenalidomide in patients with poor prognosis (high MIPI score at baseline) and the 
elderly, who represent the majority of patients with relapsed/refractory MCL, is of 
particular clinical relevance. 
 Previous subgroup analyses for lenalidomide were conducted in the MCL-001 
study, which evaluated lenalidomide in 134 MCL patients who had experienced relapse 
after or whose disease was refractory to bortezomib (Goy, et al 2013). Because MCL-
001 did not have a control arm, the subgroup analyses evaluated the impact of baseline 
factors on ORR and duration of response (primary study endpoints). Lenalidomide 
treatment effects were consistent across subgroups in MCL-001, with high LDH 
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identified as the only significant factor for lower activity in the univariate and multivariate 
analyses (Goy, et al 2013).  
 The present MCL-002 subgroup analyses confirm these findings in a 
randomized, controlled setting. High LDH is a known adverse prognostic factor in MCL 
(Hoster, et al 2014) and was identified in the current multivariate analysis as an 
independent factor for worse PFS. Notably, lenalidomide showed a significant 
improvement in PFS compared with IC in patients with high LDH. Similarly, lenalidomide 
exhibited a statistically significant PFS benefit in other high-risk subgroups, including 
patients with high baseline MIPI score, older age (≥65 years), stage III/IV disease, high 
tumor burden, and refractoriness to last prior therapy. Lenalidomide treatment was also 
associated with a non-statistically significant trends toward longer median PFS in 
several other higher-risk subgroups, including those with bulky disease (≥7 cm) and in 
those who received prior HDT and/or SCT.  
 The MCL-002 study was prospectively conducted in a large number of patients 
across multiple centers to examine PFS and was the first randomized, controlled trial of 
lenalidomide in patients with relapsed/refractory MCL. The present subgroup analyses 
were prespecified for analysis per investigator assessment. One limitation of MCL-002 
is that temsirolimus, ibrutinib, and other newer agents that are now available for use in 
MCL were not considered standard treatment when recruitment in the MCL-002 study 
began. Thus, although lenalidomide was favored over IC in the univariate and 
multivariate analyses, the results may have been influenced by the treatment options 
available in the IC arm.  
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 Several studies of temsirolimus and ibrutinib have reported similar efficacy by 
PFS or ORR across subgroups. Temsirolimus versus single-agent IC (primarily, 
gemcitabine and fludarabine) showed consistently longer PFS across sex, performance 
status, disease stage at diagnosis, bone marrow involvement, and number of prior 
regimens in exploratory subgroup analyses of a phase III trial (Hess, et al 2009) and in 
a recent retrospective analysis, across MIPI risk categories (Hess, et al 2015). 
Subgroup analyses of a single-arm phase II trial of ibrutinib in 111 patients with 
relapsed/refractory MCL found similar ORRs, irrespective of multiple baseline factors, 
including tumor bulk (≥5 and ≥10 cm cutoffs), ≥2 prior treatment regimens, and 
refractory disease (less than partial response to last prior therapy) (Wang, et al 2015). 
More recently in an open-label phase III study, ibrutinib over temsirolimus was shown to 
have improvements in PFS overall and when broken down by subgroups (Dreyling, et al 
2016).  
 Another limitation of our analysis is that, despite the relatively large size of the 
study population, MCL-002 was not powered to detect statistical differences in PFS 
between subgroups, and the subgroup analyses were prespecified to be exploratory in 
nature. Therefore, observed differences between lenalidomide and IC should not be 
overinterpreted. Similarly, the lack of statistical significance between lenalidomide and 
IC in some subgroups should be interpreted with caution. What makes lenalidomide 
unique and different from other treatments is the longevity of its responses.  
 It is interesting to consider the factors (i.e., normal LDH, no bulky disease, <3 
prior antilymphoma therapies, ≥6 months since last prior therapy) identified by our 
multivariate analysis as having a significant positive impact on PFS, in addition to 
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lenalidomide treatment. MIPI has been validated and refined for previously untreated 
patients who received chemotherapy ± rituximab (Hoster, et al 2008, Hoster, et al 
2014). In our analysis, some but not all of the MIPI-based factors were identified here as 
having a significant impact on PFS. How these factors might help risk-stratify patients in 
the relapsed/refractory setting and with newer, more targeted agents remains to be 
defined in future larger analyses.  
 In conclusion, the prespecified subgroup and multivariate analyses for study 
MCL-002 indicate that lenalidomide improves PFS compared with single-agent IC 
therapy in patients with relapsed/refractory MCL, independent of most patient 
demographic and clinical characteristics, and prior treatment history. 
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Table I. Univariate and multivariate analyses by Cox Regression on PFS by investigator assessmenta 
 Univariate analysis Multivariate analysis 
Baseline variable HR (95% CI) P value HR (95% CI) P value 
Treatment (lenalidomide versus IC) 0.65 (0.48–0.87) 0.005 0.42 (0.28–0.62) <0.001 
MIPI-based characteristics     
MIPI score at diagnosis (high versus 
low/intermediate)b 
1.57 (1.12–2.20) 0.009 — — 
MIPI score at baseline (high versus 
low/intermediate)b 
2.11 (1.57–2.83) <0.001 1.51 (1.00–2.27) 0.052 
Age, years (≥65 versus <65) 1.02 (0.75–1.38) 0.919 — — 
ECOG PS (2 versus 0-1) 1.46 (0.99–2.16) 0.053 — — 
LDH (high versus low/normal)c 2.00 (1.49–2.67) <0.001 2.02 (1.35–3.01) <0.001 
WBC (≥10 x 109/L versus <10 x 109/L) 1.55 (1.08–2.21) 0.017 — — 
Other patient characteristics     
Sex (female versus male) 0.86 (0.62–1.18) 0.348 — — 
MCL stage at diagnosis (III/IV versus I/II) 0.81 (0.46–1.42) 0.461 — — 
Tumor burden (low versus high)d 0.81 (0.60–1.08) 0.155 — — 
Bulky disease (yes versus no)e 1.40 (0.98–2.01) 0.063 1.57 (1.01–2.43) 0.045 
Bone marrow assessment (negative 
versus indeterminate/positive)f 
0.72 (0.44–1.20) 0.206 — — 
Renal function (normal versus 
moderate/severe insufficiency)g 
0.60 (0.43–0.84) 0.003 — — 
Prior treatment history     
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 Univariate analysis Multivariate analysis 
Baseline variable HR (95% CI) P value HR (95% CI) P value 
Time from MCL diagnosis to first dose (≥3 
versus <3 years) 
0.85 (0.64–1.14) 0.280 — — 
Number of prior systemic antilymphoma 
therapies: ≥3 versus <3 
1.51 (1.11–2.06) 0.009 1.75 (1.19–2.58) 0.005 
Disease status to last prior therapy 
(relapsedh versus refractory)  
0.77 (0.58–1.03) 0.075 — — 
Time from last prior therapy to first dose 
(≥6 versus <6 months) 
0.74 (0.55–0.98) 0.034 0.68 (0.47–0.97) 0.032 
Time since last rituximab to first dose 
(≥230 versus <230 days) 
0.79 (0.59–1.07) 0.127 — — 
Prior HDT (yes versus no)i 0.98 (0.68–1.42) 0.930 — — 
Prior SCT (yes versus no) 0.96 (0.66–1.39) 0.837 — — 
CR, complete response; CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; HDT, high-dose therapy; LDH, lacatate 
dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International Prognostic Index; PFS, progression-free survival; PS, performance status; 
SCT, stem cell transplantation. 
aVariables with P value <0.20 in the univariate analysis were used to select for the multivariate. Final variables were selected using a stepwise 
selection method with entry level = 0.20 and stay level = 0.15. Multivariate survival analysis using Cox's regression model was estimated using 
162 patients. 
bMIPI score = 0.03535 * age + 0.6978 * (if ECOG PS >1) +1.367 * log10 (LDH/ULN) + 0.9393 * log10 (WBC per 10-6/L). 
cHigh LDH was >3.4 µkat/L for patients aged ≤60 years and >3.5 µkat/L for those aged >60 years; low LDH was <1.8 µkat/L; normal was defined 
per local laboratory criteria. 
dHigh tumor burden was defined by at least one lesion ≥5 cm in diameter or three lesions ≥3 cm in diameter by central radiology review. 
eBulky disease was defined by at least one lesion ≥7 cm in the longest diameter by central radiology review. 
fFor estimation of bone marrow involvement by local pathologist, negative was defined as having no aggregates or only a few well-circumscribed 
lymphoid aggregates, indeterminate bone marrow was defined as having an increased number/size of lymphoid aggregates without overt 
malignancy, and positive was defined as an unequivocal malignancy. 
gNormal renal function defined as CrCl of ≥60 mL/min; moderate insufficiency had CrCl ≥30 to <60 mL/min but not requiring dialysis; severe 
insufficiency had CrCl <30 mL/min. 2 patients had severe insufficiency in this study. 
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hRelapse included patients with best response to last treatment of CR, unconfirmed CR, or partial response. 
iHDT defined as SCT, hyper-CVAD, or R-hyper-CVAD. 
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Table II. Univariate and multivariate analyses by Cox Regression on overall survival by investigator assessmenta 
 Univariate analysis Multivariate analysis 
Baseline variable HR (95% CI) P value HR (95% CI) P value 
Treatment (lenalidomide versus IC) 0.86 (0.62–1.18) 0.35 — — 
MIPI-based characteristics     
MIPI score at diagnosis (high versus 
low/intermediate)b 
1.80 (1.27–2.56) 0.001 — — 
MIPI score at baseline (high versus 
low/intermediate)b 
2.00 (1.47–2.74) < 0.001 1.49 (0.96–2.32) 0.08 
Age, years (≥65 versus <65) 1.14 (0.82–1.60) 0.44 — — 
ECOG PS (2 versus 0-1) 1.62 (1.07–2.43) 0.02 — — 
LDH (high versus low/normal)c 1.96 (1.44–2.68) < 0.001 1.50 (0.97–2.30) 0.07 
WBC (≥10 x 109/L versus <10 x 109/L) 1.42 (0.96–2.08) 0.08 — — 
Other patient characteristics     
Sex (female versus male) 0.77 (0.54–1.11) 0.16 0.54 (0.33–0.89) 0.02 
MCL stage at diagnosis (III/IV versus I/II) 0.96 (0.50–1.82) 0.89 — — 
Tumor burden (low versus high)d 0.68 (0.50–0.94) 0.02 — — 
Bulky disease (yes versus no)e 1.55 (1.06–2.25) 0.02 1.54 (0.97–2.44) 0.07 
Bone marrow assessment (negative 
versus indeterminate/positive)f 
0.71 (0.42–1.22) 0.22 — — 
Renal function (normal versus 
moderate/severe insufficiency)g 
0.71 (0.50–1.01) 0.06 — — 
Prior treatment history     
Time from MCL diagnosis to first dose (≥3 
versus <3 years) 
0.82 (0.60–1.12) 0.22 — — 
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 Univariate analysis Multivariate analysis 
Baseline variable HR (95% CI) P value HR (95% CI) P value 
Number of prior systemic antilymphoma 
therapies: ≥3 versus <3 
1.59 (1.14–2.22) 0.006 1.49 (0.98–2.25) 0.06 
Disease status to last prior therapy 
(relapsedh versus refractory)  
0.70 (0.51–0.96) 0.03 — — 
Time from last prior therapy to first dose 
(≥6 versus <6 months) 
0.60 (0.44–0.82) 0.001 0.69 (0.47–1.04) 0.08 
Time since last rituximab to first dose 
(≥230 versus <230 days) 
0.74 (0.53–1.02) 0.07 — — 
Prior HDT (yes versus no)i 1.13 (0.77–1.68) 0.53 — — 
Prior SCT (yes versus no) 1.09 (0.74–1.62) 0.66 — — 
CR, complete response; CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; HDT, high-dose therapy; LDH, lacatate 
dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International Prognostic Index; PFS, progression-free survival; PS, performance status; 
SCT, stem cell transplantation. 
aVariables with P value <0.20 in the univariate analysis were used to select for the multivariate. Final variables were selected using a stepwise 
selection method with entry level = 0.20 and stay level = 0.15. Multivariate survival analysis using Cox's regression model was estimated using 
162 patients. 
bMIPI score = 0.03535 * age + 0.6978 * (if ECOG PS >1) +1.367 * log10 (LDH/ULN) + 0.9393 * log10 (WBC per 10-6/L). 
cHigh LDH was >3.4 µkat/L for patients aged ≤60 years and >3.5 µkat/L for those aged >60 years; low LDH was <1.8 µkat/L; normal was defined 
per local laboratory criteria. 
dHigh tumor burden was defined by at least one lesion ≥5 cm in diameter or three lesions ≥3 cm in diameter by central radiology review. 
eBulky disease was defined by at least one lesion ≥7 cm in the longest diameter by central radiology review. 
fFor estimation of bone marrow involvement by local pathologist, negative was defined as having no aggregates or only a few well-circumscribed 
lymphoid aggregates, indeterminate bone marrow was defined as having an increased number/size of lymphoid aggregates without overt 
malignancy, and positive was defined as an unequivocal malignancy. 
gNormal renal function defined as CrCl of ≥60 mL/min; moderate insufficiency had CrCl ≥30 to <60 mL/min but not requiring dialysis; severe 
insufficiency had CrCl <30 mL/min. 2 patients had severe insufficiency in this study. 
hRelapse included patients with best response to last treatment of CR, unconfirmed CR, or partial response. 
iHDT defined as SCT, hyper-CVAD, or R-hyper-CVAD. 
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Figure 1. Kaplan-Meier curves of PFS in the lenalidomide versus IC treatment arms 
for all patients (A) and for patient subgroups with age ≥65 years (B), advanced MCL 
stage III/IV at diagnosis (C), high LDH at baseline (D), high tumor burden at baseline 
(E), bulky disease at baseline (F), and disease refractory to last treatment (G). 
IC, investigator’s choice; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; 
PFS, progression-free survival. 
 
Figure 2. Forest plots of treatment effects on median PFS by subgroups according to 
MIPI-based characteristics (A), other patient characteristics (B), and prior treatment 
history (C). Improved PFS to the left of the vertical line (i.e., at 1) favors lenalidomide 
and to the right of the line favors IC. Statistically significant (P ≤ 0.05) values and the 
specified factors are shown in bold . 
ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IC, investigator’s 
choice; Intermed., intermediate; LDH, lactate dehydrogenase; MCL, mantle cell 
lymphoma; MIPI, MCL International Prognostic Index; PFS, progression-free survival; 
PS, performance status; SCT, stem cell transplantation; WBC, white blood cell. 
 
Figure 3. Kaplan-Meier curves of overall survival in the lenalidomide versus IC 
treatment arms for all patients. OS, overall survival.
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Figure 1.  
A. All patients by treatment arm 
 
 
B. ≥65 years of age 
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C. Advanced MCL stage III/IV at diagnosis 
 




Final quthor’s draft of a paper accepted for publication in the British Journal of 
Haematology 2017 doi/10.1111/bjh.15025 
 28 
E. High tumor burden at baseline 
 
F. Bulky disease at baseline 
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G. Refractory to last treatment 
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Figure 2.  
A. MIPI-based characteristics  
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Figure 3. Kaplan-Meier curves of overall survival in the lenalidomide versus IC 
treatment arms for all patients. OS, overall survival.  
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Supplemental Information 
Supplemental Table I. Prespecified baseline subgroups.  
Baseline variable Subgroups 
MIPI-based characteristics  
MIPI score at diagnosisa High versus low versus intermediate 
MIPI score at baselinea High versus low versus intermediate 
Age <65 versus ≥65 years 
ECOG PS  2 versus 0-1  
LDHb Low/normal versus high 
WBC count (x109/L) 
<6.7 versus >6.7-<10 versus >10-<15  
versus ≥15  
Other patient characteristics  
Sex  Male versus female  
MCL stage at diagnosis  I/II versus III/IV  
Tumor burdenc  Low versus high 
Bulky diseased Yes versus no  
Bone marrow assessmente  Negative versus indeterminate/positive 
Renal functionf 
Normal versus moderate/severe 
insufficiency  
Prior treatment history  
Time from MCL diagnosis to first dose <3 versus ≥3 years 
Number of prior systemic 
antilymphoma therapies 
<2 versus ≥2 
<3 versus ≥3 
1, 2, 3, ≥4 
Disease status to last therapy  Relapsedg (≥PR) versus refractory 
Number of relapses 
0 versus 1 versus >1 
<2 versus ≥2 
<3 versus ≥3 
Time from last prior therapy to first 
dose 
<6 (refractory) versus ≥6 months  
Time since last rituximab to first dose  <230 versus ≥230 days 
Type of included prior therapy Rituximab, cytarabine, or fludarabine 
Prior HDTh Yes versus no 
Prior SCT  Yes versus no 
CR, complete response; CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; HDT, 
high-dose therapy; LDH, lacatate dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International 
Prognostic Index; PR, partial response; PS, performance status; SCT, stem cell transplantation. 
aMCL International Prognostic Index (MIPI) score = 0.03535 * age + 0.6978 * (if Eastern Cooperative 
Oncology Group performance status [ECOG PS] >1) * log10 (lactate dehydrogenase [LDH]/upper limit of 
normal) + 0.9393 * log10 (white blood cell [WBC] per 10-6/L). 
bHigh LDH was >3.4 µkat/L for patients aged ≤60 years and >3.5 µkat/L for those aged >60 years; low 
LDH was <1.8 µkat/L; normal was defined per local laboratory criteria. 
cHigh tumor burden was defined by at least one lesion ≥5 cm in diameter or three lesions ≥3 cm in 
diameter by central radiology review. 
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dBulky disease was defined by at least one lesion ≥7 cm in the longest diameter by central radiology 
review. 
eFor estimation of bone marrow involvement by local pathologist, negative was defined as having no 
aggregates or only a few well-circumscribed lymphoid aggregates; indeterminate bone marrow was 
defined as having an increased number/size of lymphoid aggregates without overt malignancy; and 
positive was defined as an unequivocal malignancy. 
fNormal renal function was defined as CrCl ≥60 mL/min; moderate insufficiency had CrCl ≥30 to <60 
mL/min  not requiring dialysis; severe insufficiency had CrCl <30 mL/min. 2 patients had severe 
insufficiency in this study. 
gRelapse included patients with best response to last treatment of CR, unconfirmed CR, or partial 
response 
hHDT was defined as SCT, hyper-CVAD or R-hyper-CVAD. 
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Supplemental Figure S1. Subgroup analysis of ORR at cycle 3 in the intent-to-treat 
population for lenalidomide versus IC-treated patients (investigator’s assessment; 
March 7, 2016, data cut-off). Statistical significance for P values of ORR comparisons 
was determined by Wald Χ2 test (P<0.05). IC, investigator’s choice; LDH, lactate 





Patient characteristics at 
baseline 
Lenalidomide IC 
P value n/N ORR, % n/N ORR, % 
All patients 39/170 23 6/84 7 0.002 
Age ≥65 years 27/115 24 2/57 4 0.003 
MCL stage III/IV at 
diagnosis 
34/153 22 6/79 8 0.006 
High LDH  11/73 15 0/30 0 N/A 
High tumor burden 20/81 25 1/28 4 0.034 
Bulky disease 8/37 22 1/13 8 0.295 
Refractory status 17/70 24 1/25 4 0.142 
 
